Henry Schein upgraded to Outperform from Neutral at Baird

Baird upgraded Henry Schein to Outperform from Neutral with a price target of $92, up from $81. With dental stocks underperforming the S&P 500 by 20 points year-to-date, “a lot of bad is clearly priced into the group,” the analyst tells investors in a research note. The firm says that while dental fundamentals remain challenging, investor sentiment “feels even more negative.” It believes “now is the time to tip-toe back into dental.” Baird says Henry Schein looks like a safer “core” dental name to own into 2025.